Revenio Group Oyj

Declaration of Voting Results & Voting Rights Announcements • May 24, 2016

Disclosure 343100

Revenio Group Oyj - Total number of voting rights and capital

Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, May 24, 2016 at 9:00 INCREASED NUMBER OF SHARES ENTERED INTO TRADE REGISTER 25,263 new share subscriptions based on the company's 2007C stock options approved by the Board of Directors of Revenio Group Corporation on May 9, 2016, have been entered into the trade register today. The share subscription price under 2007C option rights was 0.54 EUR per share. The subscription period for 2007C options was until May 1, 2016. After these subscriptions, the number of Revenio Group Corporation's shares and votes will rise to 7,979,406. These increases were recorded in their entirety in the unrestricted shareholders' equity fund. Revenio Group Corporation has applied for the listing of its new shares on the Nasdaq Helsinki in the same series as the company's existing shares. According to the current estimate, the new shares will be listed on May 25, 2016. Revenio Group Oyj Olli-Pekka Salovaara CEO For further information, please contact: President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 olli-pekka.salovaara@revenio.fi www.revenio.fi DISTRIBUTION: NASDAQ Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, in which Revenio holds a 53% interest. The common denominators of Revenio's business operations include screening, follow- up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2015, the Revenio Group's net sales totaled MEUR 20.3, with its operating margin for continuing operations standing at 28.4%. Revenio Group Corporation is listed on Nasdaq Helsinki. [HUG#2013607]